These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27415449)

  • 1. Investigational protease inhibitors as antiretroviral therapies.
    Midde NM; Patters BJ; Rao P; Cory TJ; Kumar S
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1189-200. PubMed ID: 27415449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
    Wensing AM; van Maarseveen NM; Nijhuis M
    Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New HIV-1 protease inhibitors in development].
    Yoshimura K; Maeda K
    Nihon Rinsho; 2002 Apr; 60(4):780-3. PubMed ID: 11968788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease inhibitor resistance update: where are we now?
    Kim R; Baxter JD
    AIDS Patient Care STDS; 2008 Apr; 22(4):267-77. PubMed ID: 18422460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
    Zeldin RK; Petruschke RA
    J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance patterns among HIV protease inhibitors.
    Kozal M
    AIDS Patient Care STDS; 2004 Apr; 18(4):199-208. PubMed ID: 15142350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational reverse transcriptase inhibitors for the treatment of HIV.
    Cory TJ; Midde NM; Rao P; Kumar S
    Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of HIV protease inhibitors as pharmacoenhancers.
    Moyle G
    AIDS Read; 2001 Feb; 11(2):87-98; quiz 107-8. PubMed ID: 11279888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitors: recent clinical trials and recommendations on use.
    Fernández-Montero JV; Barreiro P; Soriano V
    Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
    Martinez-Cajas JL; Wainberg MA
    Antiviral Res; 2007 Dec; 76(3):203-21. PubMed ID: 17673305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update and review of antiretroviral therapy.
    Piacenti FJ
    Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.